A Nephro-Obstetric outpatient clinic model

Estela Nogueira1, Rita Calça2, Iolanda Godinho1, Luisa Pinto3

1 Division of Nephrology and Renal Transplantation, Department of Medicine, Centro Hospitalar Lisboa Norte, EPE
2 Nephrology Department, Centro Hospitalar de Lisboa Ocidental, EPE
3 Department of Obstetrics, Centro Hospitalar Universitário Lisboa Norte, EPE

ABSTRACT

Chronic kidney disease (CKD) is increasing worldwide and studies estimate that around 6% of women of childbearing age suffer from kidney disease. Preconception counselling of women with CKD and their management during pregnancy requires a multidisciplinary team, with both nephrologists and obstetricians experienced in advising and taking care of women across the CKD spectrum, including dialysis patients and women with a kidney transplant.

Here, the authors describe a model of a Nephro-Obstetric outpatient clinic, created in 2011, detailing their current clinical experience in the management of this complex population of women.

Key words: Chronic kidney disease, counseling, dialysis, pregnancy, pre-natal management, renal transplantation

INTRODUCTION

Portugal has one of the highest rates of CKD in Europe. Studies estimate that around 6% of women of childbearing age have CKD, and this incidence will probably rise in the forthcoming years, due to late motherhood and increasing incidence of CKD.1

Pregnancy in patients with CKD is associated with worse outcomes than in healthy pregnant women. The management of these pregnancies is highly challenging for both nephrologists and obstetricians.1-4

Therefore, multidisciplinary specialized care is of maximum importance to minimize risks and optimize outcomes. Additionally, preconception counselling plays a crucial role in defining the safest timing for pregnancy, leading to a decrease in possible complications such as fetal malformations, renal function deterioration, preeclampsia and fetal growth restriction.

STRUCTURE OF A NEPHRO-OBSTETRIC OUTPATIENT CLINIC

The Nephro-Obstetric outpatient clinic at Centro Hospitalar Lisboa Norte/Hospital Santa Maria was created in 2011, in a collaborative initiative between the nephrology and obstetric departments.

The Maternal Fetal Clinic (MFC) was already working with a multidisciplinary team that involved rheumatology, infectiology and clinical genetics. Nephrology started its participation with the clinic at that time (2011), to assist in the care of CKD patients.

Clinical activity occurs at the obstetric department facilities on a monthly basis. Shared clinical processes allow a more efficient management and a constant communication between all the specialists involved. To optimize clinical care and reduce time consumption, patients are seen by different medical specialties on the same day. For example, a patient with polycystic kidney disease can have an appointment with the nephrologist, obstetrician and the clinical geneticist on the same day. Additionally, clinical evaluation can be completed by nutritional and nurse assessment.

PRECONCEPTION COUNSELLING AND OPTIMIZATION

Prepregnancy counselling can be quite challenging due to the scarcity of solid evidence on how to advise women with CKD of diverse etiology. Pregnancy in women with advanced CKD, stages 3 to 5, is even more delicate as fertility is decreased, the occurrence of pregnancy reduced and data on pregnancy outcomes very limited.

Women are referred by nephrologists, obstetricians and general practitioners. Counselling is made by an obstetrician and a nephrologist experienced in the management of pregnancies complicated by CKD. In complex cases, counselling is given at the same time, as a discussion concerning the possibility of anticipating renal replacement therapy is often necessary. Women’s partners are invited to attend to participate in the shared decision process.

Individualized advice is given based on the available recent scientific evidence, mainly focusing on fertility and its decrease as CKD progresses, the impact of pregnancy on kidney function, and maternal and fetal complications associated with CKD.

In cases of hereditary nephropathy, patients are additionally counselled by a clinical geneticist on the risk of transmission to the offspring.
and the possibility of prenatal diagnostic testing, preimplantation genetic diagnosis and conception via germ cell donation. In some patients, genetic diagnosis can be made for the first time as available tests have been evolving significantly in the last few years.

In women with immune mediated disease (such as glomerulonephritis or systemic rheumatic disease), baseline disease activity is thoroughly evaluated and characterized for risk stratification and establishment of the best timing for pregnancy. If the disease is stable for at least 6 months, therapy is then adjusted for conception, with a complete reassessment 3 to 6 months later, to ensure that remission is maintained with the new therapy.

**Angiotensin converting enzyme inhibitors (ACE)** should ideally be withheld at least 6 weeks before pregnancy. However, in patients with proteinuria >1g/day, UK NICE guidelines advise maintaining ACEs until conception with frequent pregnancy tests in order to achieve an early diagnosis of pregnancy. Decisions to maintain these drugs are thoroughly discussed considering fertility issues and the possibility of delayed pregnancy without nephroprotection as teratogenicity issues seem to occur mainly with second and third trimester exposure. Angiotensin receptor blockers (ARB) are stopped and converted to another anti-hypertensive drug 6 weeks before conceiving, as data regarding their safety in the first trimester is still lacking.

In **Diabetic patients**, tight glycemic and blood pressure control is warranted in the 6 months prior to conception, to achieve better outcomes in pregnancy and to decrease the risk of malformations. Management of proteinuria should also be optimized.

**Women with a kidney transplant** are advised to delay conception for at least 1 year after transplantation as this period is particularly prone to graft rejection and to potentially teratogenic infections. Contraceptive counselling is also discussed, as fertility is usually re-established during the first 6 months after transplantation. Ideal conditions for conception include good graft function (Cr <1.5mg/dl), proteinuria < 500mg/day), lack of graft rejection in the last year and absence of active teratogenic infections (namely citomegalovirus).**Assuring these conditions significantly reduces the risk of graft function deterioration and acute rejection. During pregnancy, the risk of graft rejection is low, with an incidence reported in the literature of around 3 to 4%.** Immunosuppression must be adjusted (mTOR inhibitors and mycophenolate mofetil must be withheld) with graft reevaluation 3 to 6 months later to ensure stable function with the new therapy.

In the past decade, the pregnancy rate in **women on dialysis** has been increasing, possibly due to intensive dialysis schedules, including nocturnal dialysis.**Additionally, after Hladenuwich et al’s publication of more favorable maternal and fetal outcomes during pregnancies involving intensive dialysis, counselling has changed considerably in this specific population.** Nevertheless, pregnancy outcomes are still better in transplanted women. As such, patients are usually advised to postpone pregnancy until after transplantation. However, women with advanced age or hyperimmunized women will have a narrow window of opportunity, meaning that the only possibility of conception will be while on dialysis.

When there is a high risk of graft failure, as in atypical/genetic hemolytic uremic syndrome, risk versus benefit of allowing conception while on dialysis is discussed. Pregnancy while on dialysis requires substantial life adjustment due to increased weekly dialysis time, possibly impinging on professional activity. Furthermore, being a mother while on dialysis may be considerably challenging, especially considering the possibility of having a premature child with disabilities. All these aspects should be discussed during counselling, focusing on the need to prepare adequate post-natal support.

Pregnancy is a risk factor for hyperimmunization and although it is difficult to individualize the possibility of alloimmunization, women need to acknowledge that possibility and its impact on transplantation.**At the preconception appointment, patients are given flyers with information, to help them clarify their doubts and integrate all the information they have been given, with the possibility of scheduling another appointment if needed.**

**PRENATAL MANAGEMENT OF PREGNANT WOMAN IN CKD STAGES G1 TO 5**

CKD pregnant women are evaluated monthly or twice a month until the end of the second trimester, and then twice a month or weekly in the third trimester, depending on clinical conditions.

**Blood pressure (BP)** monitoring at home is strongly recommended and records are evaluated at each appointment. Target levels in pregnant CKD patients is still a matter of debate, as solid evidence on this specific population is still lacking. Concerns over the reduction of uteroplacental blood flow with subsequent fetal harm is the main argument against treating hypertension in a manner similar to that in a nonpregnant state. Strong evidence that tight hypertensive control reduces maternal and fetal complications (CHIPS study) is lacking. However, most trials excluded patients with CKD. Furthermore, studies have reported worse maternal and fetal outcomes in CKD patients with previous chronic hypertension or poorly controlled hypertension during pregnancy.**As such, in patients with CKD, most authors aim for BP <140/90mmHg according to the American College of Obstetricians and Gynecologists (ACOG) guidelines published in 2013 and more recently (2019) from the UK National Institute for Health and Care Excellence (NICE), which target BP of 135/85mmHg and not below 110/70mmHg. ACOG Guidelines were also updated this year and recognize the need for a better control in patients with CKD, although specific levels are not defined.**

Table I and II provide hypertensive disorders definitions and anti-hypertensive agents used in CKD pregnant women.

**Blood and urine analysis** are performed every month with increased frequency (twice a month or weekly) by the second and third trimester, especially in more advanced CKD (G3–5) or when signs of complications arise, such as worsening hypertension, hemolytic anemia, thrombocytopenia, hepatic dysfunction, increase in proteinuria or serum creatinine (Scr). Renal function evaluation in pregnant women is difficult as none of the available GFR formulas are validated in pregnancy and all underestimate it. Creatinine clearance is still
the preferred method for the measurement of kidney function in pregnancy, although dilated urinary system will reduce its precision. However, this method is cumbersome, so most authors will use SCr, and this is also our practice. Renal physiological adaptation in normal pregnancy is associated with an increase in GFR of around 40% in the first trimester, due to renal plasma flow increment and other factors such as reduced glomerular intracapillary oncotic pressure. Knowledge of these changes is critical to the understanding of SCr variation during pregnancy. SCr > 0.9mg/dl is therefore considered pathological.

It is important to emphasize that during pregnancy, even subtle increases in SCr could imply a significant decrease in GFR, as was shown in a study published by Hladunewich et al. The study evaluated GFR in preeclamptic women and concluded that an increase in SCr of 0.2mg/dl, even if within the normal range, could mean a loss of GFR of about 50%. As such, we usually use serum creatinine to assess kidney function, closely monitoring even small rises.

**Proteinuria** is usually evaluated using first morning urine protein-to-creatinine ratio (PCR), although in patients with pre-existent high-level proteinuria or above >1g/day, a 24h proteinuria is performed in order to precisely detect variations among the different trimesters. Recent studies have revealed that PCR in random spot urine has poor correlation with 24h proteinuria, especially when therapeutic decisions need to be made.

To partially overcome this issue, patients are always told to collect first morning samples, and trends in protein excretion are evaluated. Pregnancy is associated with a physiologic decrease in tubular protein reabsorption. Therefore, a level of proteinuria only above 300mg/day is considered pathologic.

It is well known that pregnancy is by itself a risk factor for **venous thromboembolism**. In heavy proteinuric patients this risk is further increased, and most authors will recommend thromboprophylaxis. Data to precisely define the cut-off of proteinuria above which to start low molecular weight heparin (LMWH) are still lacking, but NICE guidelines in diabetes recommends its use above 5g/day. Prevention should also be considered in nephrotic proteinuria with severe hypoalbuminemia (below 2g/L), or in less severe proteinuria if other risk factors

---

**Table I**

Hypertensive Disorders adapted from the ACOG guidelines 2019

<table>
<thead>
<tr>
<th>Hypertension in pregnancy</th>
<th>SBP &gt; 140 mm Hg or DBP &gt; 90 mm Hg, or both, twice at least 4 hours apart</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe-range hypertension</td>
<td>SBP &gt; 160 mm Hg or DBP &gt; 110 mm Hg, or both, twice at least 4 hours apart</td>
</tr>
<tr>
<td>Chronic hypertension</td>
<td>Hypertension before pregnancy or 20 weeks of gestation; or hypertension that is diagnosed for the first time during pregnancy and that does not resolve in the postpartum period</td>
</tr>
<tr>
<td>Preeclampsia</td>
<td>Hypertension post 20 weeks of gestation in a previously normotensive patient and the new onset of 1 or more of the following: • Proteinuria &gt; 0.3g/day (24h urine) or protein/creatinine ratio &gt;0.3mg/mg or dipstick &gt;2+; • Serum creatinine &gt;1.1mg/dl or doubling of sCr in absence of renal disease; • Platelet count &lt;100,000/microL; • Aminotransferases &gt; 2 times above reference levels; • Pulmonary edema; • Cerebral or visual symptoms.</td>
</tr>
<tr>
<td>Chronic hypertension with superimposed preeclampsia</td>
<td>Preeclampsia in a woman with a history of hypertension before pregnancy or before 20 weeks of gestation • Precise definition not available and difficult in women with previous hypertension and proteinuria. • To be considered if sudden aggravation of hypertension/proteinuria and organ dysfunction (renal/hepatic/hematologic/neurologic/pulmonary) or sflt-1/PlGF compatible with PE.</td>
</tr>
</tbody>
</table>

Legend: Systolic blood pressure (SBP), diastolic blood pressure (DBP).

**Table II**

Anti-hypertensive drugs in CKD pregnant woman

<table>
<thead>
<tr>
<th>Drug</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First line</strong></td>
<td></td>
</tr>
<tr>
<td>Methyldopa 250 – 3000mg/day (divide into 2-3 doses)</td>
<td>Dose limited by side effects (headache, sedation etc.). Low effect if severe HT.</td>
</tr>
<tr>
<td>Nifedipine (long acting) 30 -120mg/day (divided into 2 doses)</td>
<td></td>
</tr>
<tr>
<td><strong>Second line</strong></td>
<td>Overall safe, but limited data. Avoid atenolol. Metoprolol has more data.</td>
</tr>
<tr>
<td>Beta blockers</td>
<td>Same effect as methyldopa. Clonidine more potent.</td>
</tr>
<tr>
<td>•Metoprolol 50 – 450mg/day (divided into 2 doses)</td>
<td>To be avoided, as it provokes diuresis in fetus and possibly volume depletion/placental perfusion</td>
</tr>
<tr>
<td>Clonidine 0.1mg – 0.9m/day (divided into 2 or 3 doses)</td>
<td></td>
</tr>
<tr>
<td>Doxazosine 4mg – 16mg/day</td>
<td></td>
</tr>
<tr>
<td>Diuretics – furosemide or thiazides</td>
<td></td>
</tr>
<tr>
<td><strong>Legend:</strong></td>
<td></td>
</tr>
</tbody>
</table>
are present, such as obesity or immobility. Prevention should be maintained until the 6th week postpartum.20

Recently published clinical practice guidelines in pregnancy and renal disease from the UK Renal Association (RA) recommends the use of thromboprophylaxis in patients with nephrotic range proteinuria, and considering its use in patients with non-nephrotic proteinuria when additional risk factors are present.21

Patients with systemic immune mediated disease with kidney involvement are carefully evaluated at preconception to discard active disease, stratify risk and optimize timing of conception. Women with lupus nephritis and proteinuria >1g/day after ACE/ARB suspension should ideally be submitted to biopsy (prepregnancy) to exclude active nephritis, which is associated with unfavorable outcomes.22 Full auto-antibodies and complement are evaluated to define the need for low dose aspirin and/or LMWH according to recently published EULAR guidelines.23 During pregnancy, immunologic monitoring is mainly performed with dsDNA antibody and complement levels, bearing in mind that C3 and C4 levels (being acute phase proteins) usually increase during normal pregnancy. Hydroxychloroquine should be maintained or added in all pregnant women with lupus as it reduces the possibility of flares (including renal flares), infection, thrombosis, congenital heart block and intrauterine growth restriction.22,24

The use of azathioprine, cyclosporine A, tacrolimus and low dose steroids during pregnancy is safe. Lupus flares can be managed with these agents. When severe flares occur, intravenous glucocorticoids pulse therapy, intravenous immunoglobulin and plasmapheresis can be considered. In recent years, several studies have revealed successful management of renal flares with tacrolimus monotherapy.25

De novo Glomerulopathy during pregnancy is rare but when it occurs, especially if associated with nephrotic syndrome or renal dysfunction, renal biopsy is warranted. It is consensual that after 30-32 weeks, no woman should be biopsied, as the risks of prematurity decrease significantly after that time and the best option would be to anticipate delivery and perform the biopsy afterwards. The best evidence on this issue comes from a systematic review of 39 studies, with 243 and 1236 biopsies done during and after pregnancy respectively. Relevant complications were found in 7% of reported biopsies performed during pregnancy versus 1% performed after delivery. Of these, 2% were major complications and occurred between the 23rd and the 26th week of pregnancy.26 As such, if necessary, biopsies should be performed before 23 weeks.

In pregnant CKD women, urine culture is performed every month. Asymptomatic bacteriuria is almost never treated, recent UK RA guidelines recommends that if renal function deteriorates and serum urea is above 15mmol/L (90mg/dl), discussion about initiating dialysis should occur. The decision to start dialysis should balance the risks, benefits and logistics of dialysis initiation in pregnancy with the risks of preterm delivery before dialysis initiation if the gestation is approaching or more than 34 weeks.

Regarding PE treatment, there is some enthusiasm regarding sFlt-1 removal by therapeutic apheresis. In a pilot study, Ravi Thadhani showed that this therapy could prolong pregnancy by 8 to 15 days, with one or more sessions of apheresis. However, a proof-of-concept trial (SAVE) is ongoing and this potential therapy is still unavailable.30

In patients with CKD and PE, it is important to emphasize that there is an increased risk of pulmonary edema and, therefore, continuous and careful volemia assessment is mandatory. One of the questions that remains unanswered is what cut-off should be used to initiate dialysis in patients with advanced CKD or with CKD that progresses during pregnancy. There is insufficient data to establish this cut-off. However, considering the historical observational data that urea is fetotoxic, especially at levels above 17mmol/L (102mg/dl), the expert panel responsible for the recently published UK RA guidelines recommends that if renal function deteriorates and serum urea is above 15mmol/L (90mg/dl), discussion about initiating dialysis should occur. The decision to start dialysis should balance the risks, benefits and logistics of dialysis initiation in pregnancy with the risks of preterm delivery before dialysis initiation if the gestation is approaching or more than 34 weeks.
Additionally, the guideline committee advocates that until there is strong evidence to intensify dialysis in patients commencing dialysis during pregnancy, initiation of dialytic therapy during pregnancy should be ‘gentle’ (example 2h 3times a week), with subsequent titration according to biochemical parameters, as well as maternal and fetal wellbeing. 

As mentioned above, in patients with diabetic nephropathy, both glycemic and blood pressure control and proteinuria management must be optimized in preconception to reduce the incidence of complications, including malformations. During pregnancy, proteinuria frequently increases, due to hyperfiltration and an increase in glomerular permeability associated with the progressive rise of sFlt-1 level during gestation. In our outpatient clinic, thromboprophylaxis is usually initiated when proteinuria reaches nephrotic levels, as defined by UK RA guidelines. Tight glycemic control must be achieved and consequently patients are closely managed by both an endocrinologist and a nutritionist experienced in obstetrics.

**Prenatal management of pregnant women on dialysis**

Historically, patients on dialysis would be discouraged from getting pregnant, as maternal and fetal outcomes reported in the literature were very poor. Furthermore, the available data were sparse, as the fertility rate in dialysis women was very low, with a pregnancy incidence of 0.3 per 100 patient years. Over the last decades, and possibly due to innovation in dialysis, pregnancy rates have progressively increased, with rates of 1 to 7% in some series, even reaching 15 to 20%. Therefore, some authors discuss the possibility of increasing dialysis dose or switching to nocturnal dialysis to increase the possibility of fertility in some patients.

Increased uremic clearance with reduction of prolactin levels could play a role in normalizing the usual disturbance in the hypothalamic–pituitary–gonadal axis that is seen in childbearing-age women on dialysis. This was shown in the Toronto study in which intensively dialyzed patients experienced the return of regular menstrual cycles and an increased fertility incidence of 15 to 20%. Therefore, some authors discuss the possibility of increasing dialysis dose or switching to nocturnal dialysis to increase the possibility of fertility in some patients.

Pregnancy in women on peritoneal dialysis (PD) seems to be less likely than in women on hemodialysis, possibly due to hypertonic dextrose solutions and the fluid-filled peritoneum that can interfere with ovum transit to the uterus. Although the reasons remain unclear, if fertility is pursued, transition to intensive hemodialysis schedules should probably be proposed.

**Pregnancy diagnosis in women on dialysis** is typically delayed (sometimes until the 20th week of gestation or later) since menses are frequently irregular and weight gain, nausea and vomiting are common in these patients. Furthermore, human chorionic gonadotropin levels are frequently positive (low levels) in women with CKD stage 5, as they correlate inversely with creatinine clearance, contributing to uncertainty in the diagnosis. If pregnancy is suspected, an ultrasound should be performed as soon as possible to confirm the diagnosis, fetal viability and gestational age.

The most important paradigm shift in pregnancies with ESRD relies on the recent evidence that increasing dose-delivered dialysis improves pregnancy outcomes. The Hladunewich group published a study comparing pregnancy outcomes from 22 pregnancies in the Toronto Pregnancy and Kidney Disease Clinic and Registry (2000–2013) with outcomes from 70 pregnancies in the American Registry for Pregnancy in Dialysis Patients (1990–2011). Patients dialyzed 20h/week had a 48% live birth rate compared to 85% in woman dialyzed 36h per week. Additionally, duration of pregnancy increased significantly from 27 weeks to 36 weeks, and birth weight raised from 1748 vs 2118g.

Currently, it is consensual that dialysis dose should be increased in pregnancy. Dialysis prescription itself varies according to different practices. Renal residual function must be considered when defining dialysis dose. Recently published UK RA guidelines recommend switching from PD to HD and prescribing long, frequent hemodialysis, aiming for pre-dialysis urea < 75mg/dl.

Other authors will aim for pre-dialysis urea of 60-90 mg/dl and define that minimum dialysis dose in pregnancy will be typically 36h/week (6h/day, 6 times a week).

At our unit, we aim for 36h/week, with urea < 60mg/dl, although this schedule is highly challenging for patients requiring individualization, especially in patients with residual renal function. Ideally, patients should be on nocturnal dialysis, but dialysis centers usually do not have the availability to offer this dialysis schedule, except during the day.

Dialysis prescription, therapy and diet should also be adapted to pregnancy, as detailed in Table III.

During the second and third trimesters, blood analysis should be performed at least biweekly, and then weekly if blood pressure levels increase or if there is any sign of PE. It is very difficult to diagnose PE in patients on dialysis. This diagnosis relies mainly on BP aggravation, hemolytic anemia, thrombocytopenia and liver dysfunction. Signs are frequently mild, but should always be closely monitored, as should fetal well-being. sFlt1/PlGF ratio can be helpful in the diagnosis of PE.

Regarding obstetric care, it is worth emphasizing that first trimester screening tests have flaws where dialysis patients are concerned. Therefore, if possible, screening with cell-free DNA in maternal blood should be offered.

Fetal monitoring involves obstetric ultrasounds at 12, 21, 28, 32 and 36 weeks and weekly cardiotocography starting at 32 weeks.

If magnesium sulphate is used for neuroprotection or in the prevention of eclampsia, a loading dose of 4 to 6 g is administered over 20 to 30 minutes, with close monitoring of magnesium levels and signs of toxicity. Maintenance dose is not used in these patients.

Route of delivery should be decided according to obstetric criteria.

It is of utmost importance that these patients are surveyed at a tertiary center, where both obstetrics, nephrology and neonatology can provide specialized care in such a complex situation.
PRENATAL MANAGEMENT IN PREGNANT WOMAN WITH RENAL TRANSPLANT

Renal transplant patients have an increased risk of PE (~30%), and AAS is usually started between the 12th and the 16th weeks, as recommended by UK RA clinical practice guidelines on post-operative care of kidney transplant recipients. After conception, careful monitoring of calcineurin inhibitor serum levels is carried out, as there is usually an abrupt decrease of CsA and tacrolimus levels in the first trimester. In some patients, pre-pregnancy dose can be duplicated without reaching therapeutic levels. However, there is some evidence that during pregnancy, unbound tacrolimus levels are stable even when whole blood tacrolimus decreases, which means that there is a possibility that we should not increase the dose. Unfortunately, measuring unbound tacrolimus is unfeasible in clinical practice. Currently, although some authors advocate that adjusting the dose is unnecessary, most renal physicians will increase tacrolimus and CsA dose targeting therapeutic levels, as suggested by available guidelines. We usually increase the dose to reach tacrolimus levels of 4–5 ng/L, and these levels are evaluated biweekly in the first trimester and monthly afterwards. In some patients, especially in those in which the calcineurin inhibitor dose is significantly increased (even with therapeutic levels), hyperkalemia or graft dysfunction can occur without any other cause, and usually resolve after reducing the dosage.

Although rejection episodes are rare during pregnancy (around 3 to 4%), when they occur, therapy will include iv steroids, plasmapheresis, ivlg or rituximab. There is currently insufficient data to recommend the use of rituximab during pregnancy as it may causes neonatal B-cell depletion and although there are several case reports, its long-term effect is still unknown.

Pregnancy is a risk factor for hyperimmunization. Studies reveal that around 30% of patients can develop anti-HLA antibodies during pregnancy. Additionally, 50 to 75% of patients will have anti-HLA antibodies if more sensitive detection methods are used (single bed antigens). However, anti-HLA levels seem to decrease and/or disappear 1 to 2 years after gestation, possibly because fetal-antigens-primed maternal T cells are hypofunctional and highly sensitive to immunosuppression. Nevertheless, anecdotal case reports of acute rejection following pregnancy have been reported, with donor specific antibody emergence, especially when fetus/paternal HLA typing is similar to that of the donor.

Currently, there is no evidence to support increasing immunosuppression postpartum, but close surveillance in patients with donor/father shared HLA typing could be helpful in identifying patients at risk of rejection.

POSTNATAL MANAGEMENT OF WOMEN WITH RENAL DISEASE

Non-steroidal anti-inflammatories (NSAIDs) are frequently prescribed as postpartum analgesics, but in women with CKD those agents should be avoided, especially in patients with eGFR <30ml/min due to the possibility of renal dysfunction or fluid retention.

After delivery, renal function and proteinuria should be evaluated, particularly in patients with acute kidney injury and/or de novo proteinuria/increased baseline proteinuria. In PE, proteinuria usually declines fairly rapidly, sometimes remitting entirely in the first month, although in some cases this can take months to happen. As such, if PE was suspected and renal function is improving, renal biopsy will be delayed for at least 3 months. Importantly, PE can occur with active
CONCLUSIONS

urine sediment and histologic changes can persist for as long as 18 months. For these reasons, an early biopsy could be misleading.

All patients with CKD or a new diagnosis of renal disease are evaluated postpartum at the Nephro-Obstetric clinic. Patients with previously known CKD are then referred to their renal physician in order to maintain follow up.

After birth, antihypertensive therapy needs to be adjusted, especially in patients with PE or hypertension aggravation during pregnancy. Patients under immunosuppression with a calcineurin inhibitor should have their levels evaluated for new dose adjustment in order to avoid nephrotoxicity.

Counselling regarding breastfeeding is of paramount importance, as most CKD patients will have doubts about the safety of therapy. The LactMed database from the National Institutes of Health (NIH) provides an excellent tool regarding the safety of drugs while breastfeeding, as it is updated monthly. Methyldopa, nifedipine and metoprolol are safe during lactation. ACE inhibitors can and should be used in women with hypertension and proteinuria, and of those, enalapril or captopril represent the best option, barely being detectable in breast milk. There is insufficient data on the use of ARB during breastfeeding, and diuretics are generally avoided because of the potential to reduce milk production. Immunosuppressive agents such as low dose corticosteroids, tacrolimus, CsA, azathioprine and hydroxychloroquine are safe during lactation. Small studies quantifying the quantity of azathioprine, tacrolimus, and CsA in breastmilk suggest that the dose received by the new-born is only a small percentage (usually <1%) of the maternal dose and unlikely to cause injury.

On the contrary, mycophenolate mofetil, mTORi, rituximab, cyclophosphamide and ecullizumab should be avoided due to limited data.

COUNCILS

Pregnancy in women with CKD and women with a renal transplant should be planned in advance. Therefore, nephrologists and obstetricians should pursue active counselling to reduce the risks and optimize maternal and fetal outcomes. Management of these women is complex and should involve a multidisciplinary team, closely monitoring maternal and fetal wellbeing during pregnancy.

Disclosure of potential conflicts of interest: none declared

References


Correspondence to: Estela Nogueira, MD
Division of Nephrology and Renal Transplantation, Department of Medicine, Centro Hospitalar Lisboa Norte, EPE;
Av. Prof. Egas Moniz MB, 1649-028 Lisboa
E-mail: estelanogueira@gmail.com